Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Tirzepatide came off the FDAs official drug shortage list in December 2024, and semaglutide followed in February 2025, eliminating the legal pathway that allowed compounding pharmacies to produce copies of the drugs
Benefits Primary Benefits Research on AHK-Cu has primarily examined its potential to support the hair growth cycle, particularly extending the anagen (growth) phase
Commonly reported side effects include mild pain, swelling, or itching at the injection site and sometimes nausea
IGF-1 LR3 Reconstitution Reference (1 mg / 1,000 mcg vial) BAC water added 1 mL Concentration 1,000 mcg/mL 20 mcg dose 0.02 mL (2 units) 40 mcg dose 0.04 mL (4 units) 50 mcg dose 0.05 mL (5 units) 80 mcg dose 0.08 mL (8 units) 100 mcg dose 0.10 mL (10 units) BAC water added 2 mL Concentration 500 mcg/mL 20 mcg dose 0.04 mL (4 units) 40 mcg dose 0.08 mL (8 units) 50 mcg dose 0.10 mL (10 units) 80 mcg dose 0.16 mL (16 units) 100 mcg dose 0.20 mL (20 units) BAC water added 3 mL Concentration 333 mcg/mL 20 mcg dose 0.06 mL (6 units) 40 mcg dose 0.12 mL (12 units) 50 mcg dose 0.15 mL (15 units) 80 mcg dose 0.24 mL (24 units) 100 mcg dose 0.30 mL (30 units) Units refer to U-100 insulin syringe markings
US$ 29.75
US$ 29.74
US$ 29.48
US$ 27.68
US$ 24.08
US$ 26.51
US$ 24.21
US$ 29.61
US$ 21.47
